Get startedLog in
    Picture of Integra LifeSciences Holdings logo

    IART — Integra LifeSciences Holdings Cashflow Statement

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMid CapNeutral
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Integra LifeSciences Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    2025
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:10-K10-K10-K10-K10-K
    Standards:
    USG
    USG
    USG
    USG
    USG
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line16918167.7-6.94-516
    Depreciation
    Deferred Taxes
    Non-Cash Items8.119.6342.247.2515
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital18.2-39.4-81.6-31-33.7
    Change in Accounts Receivable
    Change in Inventories
    Change in Prepaid Expenses
    Change in Other Assets
    Change in Payable / Accrued Expenses
    Change in Other Liabilities
    Cash from Operating Activities31226414012950.4
    Capital Expenditures-48.1-47.1-66.9-114-95.6
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items-113-11.5-27.3-276-12.4
    Acquisition of Business
    Sale of Business
    Sale of Fixed Assets
    Sale/Maturity of Investment
    Change in Net Investments
    Purchase of Investments
    Other Investing Cash Flow
    Cash from Investing Activities-161-58.6-94.2-391-108
    Financing Cash Flow Items-5.05-24.6-13.7-15.4-23.2
    Other Financing Cash Flow
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities-98.2-252-23023828.3
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash43.3-56.8-180-30-11.3